Biocon's insulin analog misses Phase III endpoint

Biocon Ltd. (NSE:BIOCON; BSE:BIOCON) said IN-105 missed the primary endpoint of reducing HbA1c by 0.7% compared to placebo at six months in a Phase III trial to treat Type II diabetes. Biocon said tha...